Loading organizations...
§ Private Profile · Lexington, MA, USA
SynapDx is a technology company.
SynapDx develops laboratory diagnostic services focused on the early detection of autism and neurodevelopmental disorders. The company provides blood-based diagnostic tests, leveraging biotechnological advancements for precise identification. Their core offering enables a scientific method for earlier diagnosis, serving the medical community and patients seeking improved diagnostic pathways.
SynapDx was founded in 2010, establishing its headquarters in Lexington. The company's inception stemmed from the critical insight that more accurate and earlier diagnostic tools for autism were essential. While specific founder details are not publicly available, the enterprise emerged from a commitment to applying blood-based testing for timely identification of neurodevelopmental conditions.
SynapDx serves patients across the United States, with its diagnostic services primarily utilized by healthcare providers. The company's long-term vision aims to fundamentally improve the diagnostic landscape for autism, focusing on facilitating earlier interventions. It is dedicated to advancing diagnostic precision within neurodevelopmental health.
SynapDx has raised $45.4M across 7 funding rounds.
SynapDx has raised $45.4M in total across 7 funding rounds.
SynapDx has raised $45.4M across 7 funding rounds. Most recently, it raised $15.4M Other Equity in July 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 22, 2013 | $15.4M Venture Round | Krishna Yeshwant | Foundation Medical Partners, Hemant Taneja, Bill Geary | Announced |
| Jul 1, 2013 | $15M Series U | — | Endeavor Venture Funds, Flare Capital Partners, General Catalyst | Announced |
| Feb 21, 2013 | $2M Venture Round | David P. King | — | Announced |
| Feb 1, 2013 | $2M Series C | Labcorp | Endeavor Venture Funds, Flare Capital Partners, General Catalyst | Announced |
| Nov 1, 2012 | $6M Series B | General Catalyst, Bill Geary | Brighton Park Capital, Flare Capital Partners | Announced |
| Oct 1, 2012 | $2M Series B | — | Endeavor Venture Funds | Announced |
| May 1, 2010 | $3M Series A | — | Brighton Park Capital, Endeavor Venture Funds, Flare Capital Partners, General Catalyst, Bain Capital Ventures, North Bridge | Announced |
SynapDx has raised $45.4M in total across 7 funding rounds.
SynapDx's investors include Krishna Yeshwant, Foundation Medical Partners, Hemant Taneja, Bill Geary, Endeavor Venture Funds, Flare Capital Partners, General Catalyst, David P. King, Labcorp, Brighton Park Capital, Bain Capital Ventures, North Bridge Venture Partners.
SynapDx (also stylized as SYNAPS Dx) is a clinical-stage diagnostics company developing innovative biomarker-based tests for early detection of neurological disorders, primarily targeting Alzheimer's disease and autism spectrum disorder (ASD). It offers products like DISCERN™, a gold-standard validated skin biopsy test that distinguishes Alzheimer's from other dementias with high precision, and has historically pursued blood-based ASD diagnostics to aid clinicians in identifying at-risk children.[2][3][4] Serving neurologists, pathologists, and healthcare providers, SynapDx addresses critical gaps in early, accurate diagnosis for devastating conditions lacking reliable non-invasive tools, enabling better disease management and intervention; the CLIA-certified lab supports high-complexity testing.[2] While early growth focused on autism (e.g., $15.4M funding in 2012 for ASD studies), momentum has shifted to Alzheimer's, reflecting pivots amid biotech challenges.[2][4]
SynapDx emerged from a research lab in Rockville, Maryland, where scientists pursued a decade-long quest to overcome limitations in Alzheimer's diagnostics, driven by founders' personal experiences with the disease's impacts.[2] The founding team includes renowned neurologists and pathologists, with leadership featuring healthcare experts like those with 20+ years in clinical programs at UnitedHealthcare’s Optum and Molina Healthcare, specializing in predictive algorithms for chronic illness detection using labs, claims, and NLP.[2] Key early milestones include licensing autism diagnostic discoveries from Children's Hospital Boston (2010) and George Washington University for blood-based ASD tests, followed by a pivotal $15.4M funding round led by Google Ventures in 2012 to advance large-scale ASD studies.[4][5] This positioned SynapDx as an early-stage lab services player, evolving from autism focus to pioneering Alzheimer's innovations like DISCERN™.[2][3]
SynapDx stands out in precision diagnostics through:
(Note: A conflicting source describes online gaming solutions for Bandarqq, likely erroneous or unrelated.[1])
SynapDx rides the precision medicine wave in neurology, capitalizing on surging demand for early biomarkers amid aging populations and autism prevalence (1 in 36 children).[2][3] Timing aligns with advances in non-invasive diagnostics—skin biopsies avoid brain scans' invasiveness—fueled by market forces like NIH funding and payer pressures for cost-effective chronic illness prediction.[2][4] It influences the ecosystem by validating novel tests (e.g., gold-standard for Alzheimer's), licensing academic IP, and bridging research to clinics, potentially accelerating companion diagnostics for emerging Alzheimer's therapies like anti-amyloid drugs.[2][5]
SynapDx is poised to expand DISCERN™ commercially, targeting broader adoption in neurology clinics amid Alzheimer's market growth (projected $15B+ by 2030). Trends like AI-enhanced biomarkers and multi-omics will shape its path, potentially reviving ASD efforts or adding tests for other dementias. Its influence may grow via partnerships, influencing how biotech shifts from symptomatic to predictive neurodiagnostics—transforming trajectories as its founders envisioned.[2]